Stephen A. Trowbridge - 17 Jul 2024 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role
EVP and CFO
Signature
/s/ Stephen A. Trowbridge
Issuer symbol
ANGO
Transactions as of
17 Jul 2024
Net transactions value
-$48,279
Form type
4
Filing time
02 Aug 2024, 21:48:10 UTC
Previous filing
04 Mar 2024
Next filing
25 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANGO Common Stock Options Exercise $0 +11,142 +6.7% $0.000000 177,612 17 Jul 2024 Direct F1
transaction ANGO Common Stock Tax liability $29,718 -4,016 -2.3% $7.40 173,596 17 Jul 2024 Direct F2
transaction ANGO Common Stock Tax liability $18,560 -2,585 -1.5% $7.18 171,011 19 Jul 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANGO Performance Right Options Exercise $0 +14,817 $0.000000* 0 17 Jul 2024 Common Stock 14,817 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This acquisition of 11,142 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.
F2 The exempt disposition of 4,016 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.
F3 The exempt disposition of 2,585 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 19, 2023.
F4 On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.